Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

Returns on capital

Theravance Biopharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

35.7%

avg 42.9%

ROIC

-2.4%

avg -45.6%

ROA

21.8%

avg -20.8%

Analysis

ROE is currently the strongest return metric at 35.7% versus its period average of 42.9%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Rick E. Winningham

Chief Executive Officer & DirectorUSD 1.47M660<0.01%

Aine Miller

Senior Vice President of Development & Head of Ireland OfficeUSD 747.32K490<0.01%

Brett A. Grimaud

Senior Vice President, General Counsel & SecretaryUSD 690.87K520<0.01%

Rhonda F. Farnum

Chief Business Officer and Senior Vice President of Commercial & Medical AffairsUSD 682.94K61——

Aziz Sawaf

Senior VP of Operations Strategy & CFOUSD 660.15K440<0.01%

Stuart Knight

Senior Vice President of IT&I and Chief Information Officer————

Stacy L. Pryce

Senior Vice President & Chief Strategy Officer————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 23, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

17

$7.84M

Net Transaction Value

−$7.84M

Net selling

Most Active

Farnum Rhonda

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 15, 26

Farnum Rhonda

Direct

Sell$56.7K
Sep 15, 26

Farnum Rhonda

Direct

Sell$56.7K
Sep 15, 26

Farnum Rhonda

Direct

Sell$113.4K
Jul 1, 26

Samaha Eli

Indirect

Sell$642.6K
Jun 30, 26

Samaha Eli

Indirect

Sell$428.8K
Jun 29, 26

Samaha Eli

Indirect

Sell$4.7M
Jun 15, 26

Farnum Rhonda

Direct

Sell$54.6K
Jun 15, 26

Farnum Rhonda

Direct

Sell$54.5K
Jun 15, 26

Farnum Rhonda

Direct

Sell$109.1K
Mar 16, 26

Farnum Rhonda

Direct

Sell$108.1K

1–10 of 17

Summary

Insiders reported 0 buys worth $0.00 and 17 sells worth $7.84M over the last 12 months. That adds up to net selling of $7.84M. Farnum Rhonda was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
-4.5% (5yr)1 analysts
RevenueN/AN/A+27.9%
+1.2% (5yr)2 analysts
Net IncomeN/AN/A-50.5%
-4.4% (5yr)2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +27.9% over three years. Forward estimates point to Revenue at +1.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Theravance Biopharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TBPH's management, answered from reported figures.

Who manages TBPH?

Theravance Biopharma, Inc. (TBPH) lists 7 active executives. The top listed executive is Aziz Sawaf, Senior VP of Operations Strategy & CFO.

Are TBPH insiders buying or selling?

Recent insider activity shows net selling of $27.59M.